共 50 条
PI3K inhibitors in thrombosis and cardiovascular disease
被引:65
|作者:
Durrant, Tom N.
[1
]
Hers, Ingeborg
[2
]
机构:
[1] Univ Oxford, Dept Chem, Oxford OX1 3QZ, England
[2] Sch Physiol Pharmacol & Neurosci, Biomed Sci Bldg,Univ Walk, Bristol BS8 1TD, Avon, England
来源:
CLINICAL AND TRANSLATIONAL MEDICINE
|
2020年
/
9卷
/
01期
关键词:
Cardiovascular disease;
Thrombosis;
Platelets;
Phosphoinositide;
3-kinase;
PI3K;
Phosphoinositides;
Cellular signalling;
II PHOSPHOINOSITIDE 3-KINASE;
REGULATES PLATELET ACTIVATION;
PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE;
PI3K-GAMMA INHIBITION;
P110-ALPHA ISOFORM;
P110-BETA SUBUNIT;
CRYSTAL-STRUCTURE;
P2Y(12) RECEPTOR;
DOSE-ESCALATION;
CELL-MIGRATION;
D O I:
10.1186/s40169-020-0261-6
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate important intracellular signalling and vesicle trafficking events via the generation of 3-phosphoinositides. Comprising eight core isoforms across three classes, the PI3K family displays broad expression and function throughout mammalian tissues, and the (patho)physiological roles of these enzymes in the cardiovascular system present the PI3Ks as potential therapeutic targets in settings such as thrombosis, atherosclerosis and heart failure. This review will discuss the PI3K enzymes and their roles in cardiovascular physiology and disease, with a particular focus on platelet function and thrombosis. The current progress and future potential of targeting the PI3K enzymes for therapeutic benefit in cardiovascular disease will be considered, while the challenges of developing drugs against these master cellular regulators will be discussed.
引用
收藏
页数:21
相关论文